Spyre Therapeutics | ARS: Annual Report to Security Holders
Spyre Therapeutics | DEFA14A: Others
Spyre Therapeutics | DEF 14A: Definitive information statements
Spyre Therapeutics | EFFECT: Others
Spyre Therapeutics | EFFECT: Others
Spyre Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Spyre Therapeutics | 8-K: Current report
Spyre Therapeutics | CORRESP: CORRESP
Spyre Therapeutics | UPLOAD: Others
Spyre Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Spyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Spyre Therapeutics | 10-K: FY2024 Annual Report
Spyre Therapeutics | SCHEDULE 13G/A: Others
Spyre Therapeutics | SCHEDULE 13G/A: Others
Spyre Therapeutics | SCHEDULE 13G/A: Others
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Burrows Scott L
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sloan Sheldon
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Turtle Cameron
Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer King-Jones Heidy